Repurposing a tricyclic antidepressant in tumor and metabolism disease treatment through fatty acid uptake inhibition

J Exp Med. 2023 Mar 6;220(3):e20221316. doi: 10.1084/jem.20221316. Epub 2022 Dec 15.

Abstract

Fatty acid uptake is essential for cell physiological function, but detailed mechanisms remain unclear. Here, we generated an acetyl-CoA carboxylases (ACC1/2) double-knockout cell line, which lacked fatty acid biosynthesis and survived on serum fatty acids and was used to screen for fatty acid uptake inhibitors. We identified a Food and Drug Administration-approved tricyclic antidepressant, nortriptyline, that potently blocked fatty acid uptake both in vitro and in vivo. We also characterized underlying mechanisms whereby nortriptyline provoked lysosomes to release protons and induce cell acidification to suppress macropinocytosis, which accounted for fatty acid endocytosis. Furthermore, nortriptyline alone or in combination with ND-646, a selective ACC1/2 inhibitor, significantly repressed tumor growth, lipogenesis, and hepatic steatosis in mice. Therefore, we show that cells actively take up fatty acids through macropinocytosis, and we provide a potential strategy suppressing tumor growth, lipogenesis, and hepatic steatosis through controlling the cellular level of fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents, Tricyclic / metabolism
  • Antidepressive Agents, Tricyclic / pharmacology
  • Antidepressive Agents, Tricyclic / therapeutic use
  • Drug Repositioning
  • Fatty Acids / metabolism
  • Fatty Liver* / pathology
  • Liver / metabolism
  • Metabolic Diseases* / metabolism
  • Mice
  • Neoplasms* / pathology
  • Nortriptyline / metabolism
  • Nortriptyline / therapeutic use

Substances

  • Fatty Acids
  • Antidepressive Agents, Tricyclic
  • Nortriptyline